chemotherapy plus metformin reduces recurrence of ovarian cancer
- Conditions
- Ovarian cancer.Malignant neoplasm of ovary
- Registration Number
- IRCT2016022726788N1
- Lead Sponsor
- Vice chancellor of research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 70
all women with histopathologic diagnosis of epithelial ovarian carcinoma undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy in shahid faghihi hospital(shiraz)march 2011 to march 2015 were included.
those with the following criteria were excluded from the study:
diabetic patients; patients with liver or gastrointestinal disorders or renal failure; patients unable to tolerate metformin; patients who received neoadjuvant chemotherapy before cytoreductive surgery; patients whose ovarian cancer is secondary to other cancers
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2 year recurrence rate. Timepoint: 2 years. Method of measurement: Visit.
- Secondary Outcome Measures
Name Time Method Disease free survival. Timepoint: 2-4 years. Method of measurement: Visit.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.